Pfizer Inc. (NYSE:PFE) Shares Sold by Community Bank & Trust Waco Texas

Community Bank & Trust Waco Texas decreased its position in Pfizer Inc. (NYSE:PFE) by 37.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,446 shares of the biopharmaceutical company’s stock after selling 51,353 shares during the quarter. Community Bank & Trust Waco Texas’ holdings in Pfizer were worth $2,431,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its stake in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after purchasing an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC purchased a new position in Pfizer in the 4th quarter worth about $255,000. Brookstone Capital Management increased its stake in Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after purchasing an additional 212,369 shares in the last quarter. ETF Store Inc. boosted its position in Pfizer by 12.0% during the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares during the period. Finally, KLCM Advisors Inc. boosted its position in Pfizer by 75.0% during the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after acquiring an additional 74,487 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on PFE. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Finally, TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Trading Down 0.8 %

PFE traded down $0.20 on Wednesday, reaching $26.12. 8,024,600 shares of the company traded hands, compared to its average volume of 41,667,422. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market cap of $147.91 billion, a P/E ratio of 72.72, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61. The firm has a fifty day simple moving average of $27.07 and a two-hundred day simple moving average of $28.52. Pfizer Inc. has a one year low of $25.23 and a one year high of $40.37.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period last year, the business earned $1.14 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.